Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfamethoxazole + trimethoprim (Shanghai New Asiatic Pharmaceutical)
- Development stage
- Phase 4
- Lead developer
- Shanghai New Asiatic Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xin Nuo Ming (新诺明) is a Chinese trade name for the antibacterial combination of sulfamethoxazole and trimethoprim, commonly known as co-trimoxazole. Sulfamethoxazole is a sulfonamide that inhibits the bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase, which prevents the reduction of dihydrofolic acid to tetrahydrofolic acid. Together, these two agents produce a synergistic effect by blocking two consecutive steps in the bacterial biosynthesis of essential nucleic acids and proteins. This combination is used to treat a wide range of bacterial infections, including urinary tract infections, acute otitis media, and shigellosis, and is a primary treatment for Pneumocystis jirovecii pneumonia. Shanghai New Asia Pharmaceutical Minhang Co., Ltd. is a key developer and manufacturer of this product in China.
- Brand names
- Xin Nuo MingBactrimSeptraFu Fang Xin Nuo Ming
- Other names
- co-trimoxazoleSMZ-TMPTMP-SMZcotrimoxazole
02
Targets
DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on sulfamethoxazole + trimethoprim (Shanghai New Asiatic Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfamethoxazole + trimethoprim (Shanghai New Asiatic Pharmaceutical).